by Barry101 | May 31, 2018 | Press Release
Earlier Studies Showed Ampligen Produced a More Favorable Ratio of Killer T cells to Regulatory T cells in the Tumor Microenvironment, a Key to Improving Checkpoint Blockade TherapyORLANDO, Fla., May 31, 2018 — Roswell Park Comprehensive Cancer Center (Roswell...
by Barry101 | May 16, 2018 | Press Release
ORLANDO, Fla., May 16, 2018 — In a release issued earlier today by Hemispherx Biopharma, Inc. (NYSE American:HEB) with the same headline, the net loss from operations was incorrect in the fourth paragraph. It should say $0.07 per share, not $0.70 per share....
by Barry101 | May 16, 2018 | Press Release
ORLANDO, Fla., May 16, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), an advanced specialty pharmaceutical company engaged in the treatment of serious and debilitating disorders through the development of its immunology products Ampligen® and...
by Barry101 | May 14, 2018 | Press Release
ORLANDO, Fla., May 14, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB) announced today that it will be presenting at the 4th Annual Immuno-Oncology: BD&L and Investment Forum on Friday, June 1 at 3:40PM CDT (the time may be subject to changes...
by Barry101 | May 10, 2018 | Press Release
ORLANDO, Fla., May 10, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB) announced today that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June 4 at 11:00 AM PT (the time may be subject to changes depending on the conference...
